NCT04537832 (ENVISION) is a clinical trial of No Intervention in Dravet Syndrome, sponsored by Encoded Therapeutics.

Who is sponsoring NCT04537832?

NCT04537832 is sponsored by Encoded Therapeutics.

What drugs are being tested in NCT04537832?

Interventions in NCT04537832: No Intervention.

What condition does NCT04537832 study?

NCT04537832 studies Dravet Syndrome.

Is NCT04537832 still recruiting?

NCT04537832 is currently terminated. Last updated 12 June 2023.

Last reviewed 2023-06-12 · How we verify

NCT04537832: ENVISION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies

Terminated Last updated 12 June 2023

What this trial tests

trial testing No Intervention in Dravet Syndrome in 58 participants. Terminated before completion.

Timeline

18 January 2021

Primary endpoint
31 March 2023

31 March 2023

Quick facts

Lead sponsor	Encoded Therapeutics
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	58
Start date	18 January 2021
Primary completion	31 March 2023
Estimated completion	31 March 2023
Sites	16 locations across United Kingdom, United States, Australia, Spain

Drugs / interventions tested

No Intervention

Conditions studied

Dravet Syndrome — all drugs for Dravet Syndrome →

Sponsor

Encoded Therapeutics — full company profile →

Who can join

Adults 6 Months to 60 Months, any sex, with Dravet Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, prospective, 2-year observational study in infants and children with developmental and epileptic encephalopathies (DEEs). The DEE currently being investigated is SCN1A-positive Dravet Syndrome.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies.
Brock DC, Demarest S, Benke TA. · · 2021 · cited 10× · PMID 34595733 · DOI 10.1007/s13311-021-01123-5
Characterizing early behavioral and social-emotional problems in young children with SCN1A+ Dravet syndrome: Findings from the ENVISION prospective natural history study.
Scheffer IE, Perry MS, Sullivan J, Boronat S, et al · · 2026 · PMID 41627953 · DOI 10.1002/epi.70127
Cognitive stagnation and executive function deficits in young children with SCN1A+ Dravet syndrome: Detailed characterization of onset, progression, and impact in the ENVISION natural history study.
Sullivan J, Perry MS, Scheffer IE, Wheless J, et al · · 2026 · PMID 41251148 · DOI 10.1111/epi.70015

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting

Other recruiting trials for Dravet Syndrome

Currently open trials in the same condition.

NCT07251673 — Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation · recruiting
NCT06401538 — BMB-101 in Absence Epilepsy and DEE · Phase 2 · recruiting
NCT06660394 — A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) · Phase 3 · recruiting
NCT06118255 — A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less · Phase 3 · active not recruiting
NCT06504511 — SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04537832 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Encoded Therapeutics
Last refreshed: 12 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04537832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing